Eruptive keloids associated with aromatase inhibitor therapy

Meade, Cathy D.; Smith, Samantha; Makhzoumi, Zaineb

doi:10.1016/j.jdcr.2015.01.008

Cited by 5 publications

(7 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eruptive keloids: Eruptive keloids have been described in association with systemic disease such as scleroderma, nephrogenic systemic fibrosis, and letrozole therapy. Rather than the violaceous plaques and papules of the KS picture here, eruptive keloids present with multiple skin-colored to hyperpigmented, firm, claw-like plaques (Meade et al, 2015).…”

Section: Discussion Of Incorrect Answersmentioning

confidence: 76%

Cells to Surgery Quiz: January 2020

Hamel

Schneider

Hurst

2020

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Section: Discussion Of Incorrect Answersmentioning

confidence: 76%

Cells to Surgery Quiz: January 2020

Hamel

Schneider

Hurst

2020

Journal of Investigative Dermatology

View full text Add to dashboard Cite

“…Since keloid scars can be considered a tumor, we in fact present a secondary tumor (BCC) which arises on top of a primary tumor (keloid scar). Furthermore, He et al 13 and Meade et al 21 demonstrate another example of unusual keloid behavior of eruptive keloids associated with cancer and the clinical importance of giving long-term dynamic consideration when following a keloid patient.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous basal cell carcinoma arising within a keloid scar: a case report

Goder

Kornhaber

Bordoni

et al. 2016

OTT

View full text Add to dashboard Cite

Basal cell carcinomas (BCCs) are one of the most frequent cutaneous malignancies. The majority of BCCs are reported to occur on the auricular helix and periauricular region due to ultraviolet light exposure. Despite the frequency of BCCs, those that develop within scar tissue are rare, and the phenomenon of keloid BCCs has rarely been reported in the literature. Keloid collagen within BCCs is associated with morphoeiform characteristics, ulceration, or necrosis. Extensive keloid collagen is often seen in BCCs of the ear region, a site prone to keloid scarring. This article presents a rare case of a secondary tumor (BCC) which arose on top of a primary tumor (keloid scar) on the right auricle region in a healthy 23-year-old female after an ear piercing 2 years prior. To our knowledge, the tumor described in this case, in contrast to keloidal BCCs, has never been reported in the literature.

show abstract

Section: Dermatologic Adverse Eventsmentioning

confidence: 99%

“…Immune-mediated dAEs include erythema nodosum, subacute cutaneous lupus erythematosus, cutaneous vasculitis, and other autoimmune/connective tissue disorders ( Meade et al, 2015 ; Pathmarajah et al, 2015 ; Santoro et al, 2011 ; Williams and Leslie, 1987 ). Eruptive keloids, which have been associated with connective tissue disorders, have also been reported with AI use ( Meade et al, 2015 ). The development of immune-mediated dAEs associated with AI therapy suggests an immunomodulatory mechanism secondary to an altered hormonal environment, namely low estrogen levels ( Chao et al, 2009 ; Meade et al, 2015 ; Zarkavelis et al, 2016 ).…”

Section: Dermatologic Adverse Eventsmentioning

confidence: 99%

Art of prevention: The importance of dermatologic care when using aromatase inhibitors

Behbahani

Geisler

Kolla

et al. 2021

International Journal of Women's Dermatology

View full text Add to dashboard Cite

As of January 2021, there are more than 3.8 million women in the United States with a history of breast cancer. The current standard of care for breast cancer involves surgical resection, radiation therapy, adjuvant endocrine therapy, and/or adjuvant chemotherapy. Aromatase inhibitors (AIs) are the gold standard for endocrine therapy in postmenopausal women. Dermatologic adverse events (dAEs) associated with AIs are rare but have been reported in the literature. Commonly reported dAEs include unspecified rash, pruritus, alopecia, vulvovaginal atrophy, vasculitis, and autoimmune/connective tissue disorders. Appropriate preventative strategies and careful management considerations have the potential to optimize the comprehensive care of patients with cancer and improve quality of life. Furthermore, prevention of dAEs can lead to a reduction in cancer treatment interruptions and discontinuations. Herein, we characterize dAEs of AIs and discuss preventative management to reduce the incidence of AI therapy interruption.

show abstract

Eruptive keloids associated with aromatase inhibitor therapy

Cited by 5 publications

References 7 publications

Cells to Surgery Quiz: January 2020

Cells to Surgery Quiz: January 2020

Cutaneous basal cell carcinoma arising within a keloid scar: a case report

Art of prevention: The importance of dermatologic care when using aromatase inhibitors

Contact Info

Product

Resources

About